Canadian clinical trial registry

Go to Health Care Provider version

Centres

Study Description

This is a phase I/II study that studies the drug SNDX-5613 in patients with acute leukemia. In phase 1, the dose will be increased to find the maximum tolerated dose of SNDX-5613 and the recommended dose for the next phase will be determined. In phase 2, patients will be given the recommended phase 2 dose determined in phase 1, and the safety and efficacy in patients with various tumour mutation will be studied. 

Inclusion Criteria

• Patients must have active acute leukemia with certain genetic characteristics
• Patients must be over 30 days old 
• Patients must be up and about more than 50% of waking hours (if applicable)
• Adequate time must have passed from all previous treatments (i.e at least 60 days must have passed from last radiation treatment/stem cell infusion (if applicable))
• Adeqaute organ function
• Blood work must come back within acceptable ranges
• Patients of child bearing potential must be willing to use a highly effective method of contraception from the time of enrollment to 120 days after the last study drug dose
• Patients and/or their families/caregivers must sign a consent form outlining all assessments and requirements

Go to Health Care Provider version

Centres

Study Description

Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumour with no effective treatment and no chance of long-term survival . When this brain tumour grows back after the initial radiation therapy, it is known as progressive or recurrent DIPG.

This study will investigate how long a second treatment with radiation (re-irradiation) keeps progressive or recurrent DIPG from growing again and the overall survival of these patients. All children enrolled will be treated with re-irradiation.

Inclusion Criteria

• The patient is 17 years of age or younger at the time of first or second relapse or progression of disease
• The patient has no evidence of metastases on MRI of the brain and the spine
• The patient has received radiation in the past, given to a total dose of <60 Gy
• At least 180 days (6 months) have elapsed from the last day of primary radiation
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This clinical trial studies the side effects and how well selpercatinib (a medication taken by mouth) works in treating patients with solid tumors and brain tumours with a change in a gene called RET. 

Selpercatinib may stop the growth of cancer cells with RET gene changes by blocking the RET enzymes needed for cell growth.

Inclusion Criteria

• Age between 6 months and 21 years
• Solid tumors and brain tumours with a change in a gene called RET
• Cancer that has come back (relapse) or is not improving despite treatment (progression)
• Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

Go to Health Care Provider version

Centres

Study Description

This study is looking at a new drug called selumetinib to see if it works as well as (or better than) the usual treatment (drugs called carboplatin/vincristine) for children with a type of brain tumor called low grade glioma. This study is also checking if selumetinib is better for helping improve vision for children with these tumors. Selumetinib works by blocking a substance called an enzyme that the tumor cells need to grow, which can help kill them. The regular treatment uses different drugs that stop tumor cells from growing in different ways. This study will compare to see which method is better. 

Inclusion Criteria

• Patients must be >= 2 years and =< 21 years at the time of enrollment
• Patients must have neurofibromatosis type 1 (NF1), newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery
• Additional inclusion criteria applies for patients with optic pathway gliomas, if applicable
• Patient must meet all of the bloodwork and organ function requirements outlined in the study
• Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment
• Patients must have an adequate performance status 
• Patients must have the ability to swallow whole capsules
• All patients and/or their parents or legal guardians must sign a written informed consent.

Other inclusion and exclusion criteria applies and will be discussed with you by the study team.

Go to Health Care Provider version

Centres

Study Description

This study will evaluate the combination of two drugs called favezelimab and pembrolizumab to see how effective and safe it is for treating patients with a cancer called lymphoma. There are various different kinds of lymphoma, this study is for patients with classical Hodgkin, indolent non-Hodgkin or diffuse large B-cell lymphoma. 

Inclusion Criteria

• Participants must be 18 years of age or older 
• Participants must have a diagnosis of:
  • classical Hodgkin lymphoma (cHL)
  • diffuse large B-cell lymphoma (DLBCL)
  • indolent non-Hodgkin lymphoma (iNHL)
• Must have a tumour that can be measured on CT or MRI 
• Participant should be well enough to carry out light daily tasks, e.g., light house work, office work, normal activities

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

The purpose of this study is to find out what effects new combinations of treatment will help in treating a cancer called lymphoma. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Inclusion Criteria

• Participants must be between 16 to 65 years old to participate
• Participants must have one of the following diagnoses: 
  • Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma)
  • Previous indolent lymphoma with transformation to diffuse large B-cell lymphoma at most recent relapse
  • Unclassifiable B-cell lymphoma with indeterminate features between diffuse large B-cell lymphoma and Burkitt lymphoma
• Participants must have the presence of a protein called CD20
• Must meet all bloodwork requirements
• Participants who can bare children must have a negative pregnancy test prior to starting 
• Participants must be willing to sign a consent form and agree to the study schedule

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This study evaluates how effective a drug called plixorafenib is in participants with solid tumors or central nervous system (CNS) tumors with a genetic mutation called a BRAF fusion/BRAF V600E mutation that have progressed or come back.

Inclusion Criteria

• Male and female, ≥10 years of age, and weighing ≥30 kg.
• Diagnosis of a solid tumor or primary CNS tumor that has previously been treated with other standard therapies
• Documentation of BRAF gene fusion in tumor
• Willingness to provide informed consent and comply with study requirements 

Other inclusion and exclusion criteria apply and will be discussed with you by the study team. 

Go to Health Care Provider version

Centres

Study Description

This is a Phase 1b/2 study of the drug DAY101 in patients ≥12 years of age with solid tumours or brain tumours that have come back or progressed. This study includes 2 sub-studies, patients in sub-study A will receive the DAY-101 drug and patients in sub-study B will receive "DAY-101" and another drug called pimasertib in combination.

Inclusion Criteria

• Participants must be between 12 to 18 years old
• Participants must have a solid tumour or brain tumour that has come back (relapsed) or progressed 
• Participants must have a qualifying gene change in the tumour (MAPK pathway)
• If enrolled on study, patients and their families must agree to the study requirements by signing an informed consent/assent form

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.